Traditional drugs, diet and other factors can influence the microbiome, both positively and negatively. But Kaleido’s novel chemistries are unique in their ability to broadly affect targeted microbiome functions.
Kaleido’s novel chemistries are screened in our ex vivo microbiome platform that allows intact human microbiomes to be assayed in a high-throughput laboratory environment, ensuring high translatability and rapid advancement to the clinic.
Kaleido’s approach expands on decades of experience in the most predictive area of drug discovery - antibiotics - to robustly discover new chemistries to modulate the entire metabolic profile of the microbiome. This approach has broad implications across major therapeutic areas and organ systems.